The findings obtained in our population of COVID‐19 patients are in agreement with another recent population study showing that the ACE2‐binding site of SARS‐CoV‐2 RBD dominates the polyclonal neutralizing antibody response in COVID‐19 patients.9 This evidence concerns the gene ACE2 and COVID-19.